TY - JOUR T1 - Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling causing cell cycle block and apoptosis JF - bioRxiv DO - 10.1101/2021.05.06.442999 SP - 2021.05.06.442999 AU - Opalina Vetrichelvan AU - Priyatham Gorjala AU - Oscar Goodman, Jr AU - Ranjana Mitra Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/05/07/2021.05.06.442999.abstract N2 - Prostate cancer is the second leading cause of cancer related death in American men. Several therapies have been developed to treat advanced prostate cancer, but these therapies often have severe side effects. To improve the outcome with fewer side effects we focused on the furanocoumarin bergamottin, a natural product found in grapefruit juice and a potent CYP3A inhibitor. Our recent studies have shown that CYP3A5 inhibition can block androgen receptor (AR) signaling, critical for prostate cancer growth. We observed that bergamottin reduces prostate cancer (PC) cell growth by decreasing both total and nuclear AR (AR activation) reducing downstream AR signaling. Bergamottin’s role in reducing AR activation was confirmed by confocal microscopy studies and reduction in PSA levels. Further studies revealed that bergamottin promotes cell cycle block and accumulates G0/G1 cells. The cell cycle block was accompanied with reduction in cyclin D, cyclin B, CDK4, P-cdc2 (Y15) and P-wee1 (S642). We also observed that bergamottin triggers apoptosis in prostate cancer cell lines as evident by TUNEL staining and PARP cleavage. Our data suggest that bergamottin may be used as an adjunctive nutritional supplement to suppress prostate cancer growth and is of relevance to AA patients carrying wild type CYP3A5 often presenting aggressive disease.Competing Interest StatementThe authors have declared no competing interest. ER -